Home › Funds › DEERFIELD MANAGEMENT COMPANY, L.P. › NAMS
DEERFIELD MANAGEMENT COMPANY, L.P. position in NAMS
NEWAMSTERDAM PHARMA COMPANY · Health Care
DEERFIELD MANAGEMENT COMPANY, L.P. reported holding 4,264,789 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$144.5M, representing 1.81% of its reported portfolio and ranking #13 among its reported holdings. DEERFIELD MANAGEMENT COMPANY, L.P. has disclosed NAMS holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How DEERFIELD MANAGEMENT COMPANY, L.P.'s NAMS position evolved
DEERFIELD MANAGEMENT COMPANY, L.P. first disclosed a stake in NAMS in Q1 2024 at 667,000 shares (US$15.8M). The position peaked in Q4 2025 at 4,164,789 shares, worth US$146.1M. Across 10 filings, DEERFIELD MANAGEMENT COMPANY, L.P. increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 4,264,789 shares valued at US$144.5M. Notable position changes include a 30% increase in Q2 2024 (shares fell 10% over the following quarter), a 378% increase in Q4 2024 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 667.00K | $15.77M | New |
| Q2 2024 | 869.25K | $16.70M | Add |
| Q3 2024 | 901.75K | $14.97M | Add |
| Q4 2024 | 4.31M | $110.88M | Add |
| Q1 2025 | 4.10M | $84.01M | Reduce |
| Q2 2025 | 5.12M | $92.65M | Add |
| Q3 2025 | 4.27M | $121.34M | Reduce |
| Q4 2025 | 4.16M | $146.10M | Reduce |
| Q1 2026 | 4.26M | $136.52M | Add |
| Q2 2026 | 4.26M | $144.53M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NAMS and 13F data
NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 43 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NAMS
- Frazier Life Sciences Management, L.P. 18.09M sh · $613.03M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M sh · $323.66M · Q2 2026
- FCPM III SERVICES B.V. 8.49M sh · $287.74M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 3.81M sh · $129.00M · Q2 2026
- Maverick Capital 3.27M sh · $110.75M · Q2 2026
- MAVERICK CAPITAL LTD 3.27M sh · $110.75M · Q2 2026
- Duquesne Family Office LLC 3.07M sh · $104.05M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 2.21M sh · $74.85M · Q2 2026
- Castle Hook Partners LP 1.37M sh · $46.46M · Q2 2026
- NWI MANAGEMENT LP 702.00K sh · $23.79M · Q2 2026
- Rock Springs Capital Management LP 582.74K sh · $19.75M · Q2 2026
- First Turn Management, LLC 582.50K sh · $19.74M · Q2 2026
More on DEERFIELD MANAGEMENT COMPANY, L.P.
FAQ
How long has DEERFIELD MANAGEMENT COMPANY, L.P. held NAMS?
DEERFIELD MANAGEMENT COMPANY, L.P. has disclosed NAMS holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is DEERFIELD MANAGEMENT COMPANY, L.P.'s current position in NAMS?
As of Q2 2026, DEERFIELD MANAGEMENT COMPANY, L.P. holds 4.26M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $144.53M, representing 1.81% of its reported portfolio and ranking #13.
Has DEERFIELD MANAGEMENT COMPANY, L.P. been buying or selling NAMS?
In the latest 13F filing (Q2 2026), DEERFIELD MANAGEMENT COMPANY, L.P. held unchanged its position in NAMS. The position peaked in Q4 2025 at 4.16M shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.